+ Watch MAKO
on My Watchlist
Mako makes a robotic surgical system for knee and hip arthoplasty procedures.
As soon as investors realize that this company is on the right track and growing the stock will bounce back.
Early on, I was positive this stock would do well given Intuitive Surgical's success. However, the results of robotic surgery compared to traditional isn't as rosy as once believed. The better outcomes are there when the doctors have a lot of experience using the robotic devices. However, most using them are less experienced leading to some worse outcomes. More doctors seem to be shying away from using them for this reason.
This has Major Potential for alternative to TOTAL REPLACEMENT of KNEE, HIP, AND SHOULDER with the RIO system and aging demographics and oldest are wealthiest so this could blow up..
Something I see on another website leads me to believe most of the recent insider sales were for tax purposes. Valuation and debt numbers attractive as is the apparent bottom on the charts.
Look out! This one is looking good!
I believe Minimal invasive surgery will only become bigger and bigger. In the future, when the younger doctors grow with this technology it will only become more pervasive.
Bottomed out.Increasing Revenues.Massive growth potential.Not many competitors.
The machines are working and in use. Though the projected sales are not as high as they could be, they're still going strong, which means they're not as bad as one orthopedic surgeon top bear seems to think.
New medical instruments companies always have ups and downs, but the thing to watch is that the first loss earnings are being reduced on a steady basis as the company heads for profitability. Mako does so.
I'm going with the crowd.
A lot of money
the growth story of mako is over. q4/2012 declines from q4/2011
probably not an ISRG but still a great opportunity cinsidering its beaten-down prize and the potential for growth for robotic knee and hip surgeries.
glad i did not buy this one in real life.
It's been beaten down and has held this level for a while. If it pops, it will go fast so best to be in already. Limited downside with lots of potential upside.
Revolutionizing the way certain key surgeries are done. At bottom of a 52-week high, I think it will outperform from this price point in the short term and outperform in long term as well.
I am not only a Fool, but an orthopedic surgeon as well. That gives me a great understanding of MAKO and their products. Unfortunately, most other orthopedists that I know think that the MAKO products are just not worth the purchase price. At around $1,000,000 a piece the system must be purchased by a hospital, not a doctor. And the hospitals have a hard time figuring out how to achieve any meaniful ROI on such a major purchase. It does not provide significant decreases in operative time, it does not provide too much improvement over standard techniques in revision joint replacement rates, and does not drive very many patients to a hospital seeking this specific type of surgical implantation. I have been at two university hospitals and 2 private practice hospitals that have discussed the purchase but could not see a compelling reason to purchase. I would have to rat the long term viability of the overall concept as highly crushable, and would have to say that the future of joint replacement is going to lie in individualized instrumentation such as the Biomet Signature system where cutting guides are fabricated to match an individual's anatomy and the hospital realizes immediate gains in the bottom line via reduced costs at the time of the procedure and reduced length of stay due to the smaller incision required.
I am an anesthesiologist. The nurse director of my operating room recently told me that the Mako knee replacements are failing at a high rate, in just a year or two! Once burned, the surgeons will not trust this company's other products.
The orthopedic surgery robot maker has had a rough go of it lately. The good thing is that they continue to make progress in attracting larger hospital systems to become customers. That will carry them over the next 5 years.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions